NASDAQ: ENTX - Entera Bio Ltd.

Yield per half year: -1.09%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Entera Bio Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

more details
Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-06-28
ISIN IL0011429839
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.enterabio.com
Цена ао 1.82
Change price per day: 0% (1.81)
Change price per week: +9.66% (1.6505)
Change price per month: -7.18% (1.95)
Change price per 3 month: -20.61% (2.28)
Change price per half year: -1.09% (1.83)
Change price per year: -18.47% (2.22)
Change price per 3 year: -22.98% (2.35)
Change price per 5 year: +13.13% (1.6)
Change price per year to date: -13.81% (2.1)
All parameters

Underestimation

Title Value Grade
P/S 1352.38 1
P/BV 1.82 8
P/E 2144.95 1
EV/EBITDA -0.9348 0
Total: 4

Efficiency

Title Value Grade
ROA, % -75.55 0
ROE, % -85.59 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0439 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -94.07 0
Yield Ebitda, % -21.39 0
Yield EPS, % -65.78 0
Total: 0
More

Institutions Volume Share, %
Knoll Capital Management, LLC 3881879 10.94
TWO SIGMA SECURITIES, LLC 69441 0.2
Renaissance Technologies, LLC 57400 0.16
Geode Capital Management, LLC 17597 0.05
PNC Financial Services Group, Inc. 13000 0.04
HighTower Advisors, LLC 11830 0.03
Millennium Management LLC 10097 0.03
Morgan Stanley 1000 0
Group One Trading, L.P. 345 0
Royal Bank of Canada 200 0



Head Job title Payment Year of birth
Ms. Miranda J. Toledano M.B.A. CEO & Director 418k 1977 (48 years)
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer 296k 1978 (47 years)
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer 193k 1983 (42 years)
Dr. Gregory Burshtein Ph.D. Chief of Research & Development 1976 (49 years)

Address: Israel, Jerusalem, Kiryat Hadassah Minrav Building - open in Google maps, open in Yandex maps
Website: https://www.enterabio.com